ATE340589T1 - Impfstoffzusammensetzungen für mukosale abgabe - Google Patents

Impfstoffzusammensetzungen für mukosale abgabe

Info

Publication number
ATE340589T1
ATE340589T1 AT98120803T AT98120803T ATE340589T1 AT E340589 T1 ATE340589 T1 AT E340589T1 AT 98120803 T AT98120803 T AT 98120803T AT 98120803 T AT98120803 T AT 98120803T AT E340589 T1 ATE340589 T1 AT E340589T1
Authority
AT
Austria
Prior art keywords
vaccine compositions
tetanus
mucosal surface
provides
pertussis
Prior art date
Application number
AT98120803T
Other languages
English (en)
Inventor
Mark Roberts
Gordon Dougan
Original Assignee
Medeva Holdings Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medeva Holdings Bv filed Critical Medeva Holdings Bv
Application granted granted Critical
Publication of ATE340589T1 publication Critical patent/ATE340589T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT98120803T 1992-04-28 1993-04-28 Impfstoffzusammensetzungen für mukosale abgabe ATE340589T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929209118A GB9209118D0 (en) 1992-04-28 1992-04-28 Vaccine compositions

Publications (1)

Publication Number Publication Date
ATE340589T1 true ATE340589T1 (de) 2006-10-15

Family

ID=10714652

Family Applications (2)

Application Number Title Priority Date Filing Date
AT98120803T ATE340589T1 (de) 1992-04-28 1993-04-28 Impfstoffzusammensetzungen für mukosale abgabe
AT93911878T ATE186218T1 (de) 1992-04-28 1993-04-28 Impfstoffzusammensetzungen fuer mukosale abgabe

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT93911878T ATE186218T1 (de) 1992-04-28 1993-04-28 Impfstoffzusammensetzungen fuer mukosale abgabe

Country Status (11)

Country Link
US (1) US6562352B1 (de)
EP (2) EP0639081B1 (de)
AT (2) ATE340589T1 (de)
AU (1) AU4267093A (de)
DE (2) DE69326948T2 (de)
DK (2) DK0639081T3 (de)
ES (2) ES2141765T3 (de)
GB (1) GB9209118D0 (de)
GR (1) GR3032381T3 (de)
PT (2) PT937462E (de)
WO (1) WO1993021950A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197548B1 (en) 1990-04-02 2001-03-06 Medeva Pharma Limited Transformed Pichia expressing the pertactin antigen
US7214787B1 (en) * 1993-09-21 2007-05-08 United States Of America As Represented By The Secretary Of The Army Recombinant vaccine against botulinum neurotoxin
NZ312876A (en) * 1995-07-07 2000-06-23 Oravax Inc Intranasal, muscosal and systemic vaccination against C. difficile inducing a mucosal immune response in the gastrointestinal and/or genitourinary tracts
GB9611501D0 (en) * 1996-06-03 1996-08-07 Smithkline Beecham Biolog Vaccine compositions
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6743427B1 (en) 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US7087236B1 (en) 1998-09-01 2006-08-08 Merrion Research I Limited Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
JP4601823B2 (ja) * 1998-09-01 2010-12-22 メリオン リサーチ スリー リミテッド 経口ワクチン組成物
ATE322285T1 (de) * 1998-09-01 2006-04-15 Elan Corp Plc Verfahren zur induktion der zellulären immunantwort und parenterale impfstoff- zusammensetzungen dazu
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
GB9923060D0 (en) * 1999-09-29 1999-12-01 Chiron Spa Vaccine
US6651655B1 (en) 2000-01-18 2003-11-25 Quadrant Technologies Limited Inhaled vaccines
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MXPA04004726A (es) * 2001-11-19 2004-07-30 Becton Dickinson Co Composiciones farmaceuticas en forma particulada.
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
EP1838348B1 (de) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanisierte amyloid-beta-antikörper zur verbesserung der kognition
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
JP5889529B2 (ja) 2007-07-27 2016-03-22 ヤンセン・サイエンシズ・アイルランド・ユーシー アミロイド原性疾患の処置
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8516442D0 (en) * 1985-06-28 1985-07-31 Wellcome Found Cloned antigen
JPS632932A (ja) * 1986-06-23 1988-01-07 Teijin Ltd 経鼻投与用粉末状組成物
EP0267998A1 (de) 1986-11-17 1988-05-25 Institut Pasteur Mittel zur Unterstützung gegen Infektion und Vergiftung von Bordetella
GB8910570D0 (en) * 1989-05-08 1989-06-21 Wellcome Found Acellular vaccine
GB8914122D0 (en) * 1989-06-20 1989-08-09 Wellcome Found Polypeptide expression
IT1248735B (it) * 1990-06-21 1995-01-26 Sclavo Spa Vaccini acellulari contro la pertosse
EP0484621A3 (en) * 1990-07-11 1992-08-26 American Cyanamid Company Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens
ES2131069T3 (es) * 1991-03-05 1999-07-16 Wellcome Found Expresion de proteinas recombinantes en bacterias atenuadas.
US7532327B2 (en) * 2004-09-17 2009-05-12 Jmar Research, Inc. Systems and methods for detecting scattered light from a particle using illumination incident at an angle

Also Published As

Publication number Publication date
DE69334066T2 (de) 2007-05-03
DE69326948D1 (de) 1999-12-09
PT639081E (pt) 2000-04-28
EP0937462B1 (de) 2006-09-27
DE69334066D1 (de) 2006-11-09
US6562352B1 (en) 2003-05-13
ES2273391T3 (es) 2007-05-01
EP0639081A1 (de) 1995-02-22
ATE186218T1 (de) 1999-11-15
WO1993021950A1 (en) 1993-11-11
GB9209118D0 (en) 1992-06-10
DK0639081T3 (da) 2000-04-10
EP0639081B1 (de) 1999-11-03
DE69326948T2 (de) 2000-03-16
AU4267093A (en) 1993-11-29
EP0937462A1 (de) 1999-08-25
DK0937462T3 (da) 2007-01-29
PT937462E (pt) 2007-01-31
ES2141765T3 (es) 2000-04-01
GR3032381T3 (en) 2000-04-27

Similar Documents

Publication Publication Date Title
ATE340589T1 (de) Impfstoffzusammensetzungen für mukosale abgabe
JP3911058B2 (ja) ストレプトコックス エキワクチン
FR16C0015I2 (fr) Vaccins anticoquelucheux acellulaires et procedes de preparation correspondants
FI101632B1 (fi) Menetelmä Bordetella pertussis-toksiinin alayksikön analogien valmistamiseksi ja niitä koodaavia rekombinantti-DNA-molekyylejä
LU90203I2 (fr) Anatoxine diphtérique anatoxine tétanique trois antigènes coquelucheux purifiés (toxine pertussique tp hémagglutinine filamenteuse (haf) et pertactine (protéine de membrane externe 69 kd) et le principal antigène de surface du virus de l'hépatite b (vhb) purfié (infanrix hepb) et ses dérivés pharmaceutiquement acceptables
LU91149I2 (fr) Combinaison d'anatoxine diphtérique, d'anatoxine tétanique, d'anatoxine coquelucheuse, d'hémagglutinine filamenteuse, de pertactine et d'antigène de surface recombinant du virus d l'hépatite B(protéine S).
Podda et al. Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 kDa
FI924457A (fi) Kompositioner och behandlingsfoerfarande foer lunginflammation i djur
Roberts et al. Recombinant P. 69/pertactin: immunogenicity and protection of mice against Bordetella pertussis infection
AU725137B2 (en) Bordetella strain expressing the hybrid FHA, liposomes and vaccines
Cropley et al. Mucosal and systemic immunogenicity of a recombinant, non-ADP-ribosylating pertussis toxin: effects of formaldehyde treatment
JP5025867B2 (ja) 粘膜ＤＴＰａワクチン
EP1123711B1 (de) Attenuierte Toxine als Adjuvantien
PT94030B (pt) Processo de preparacao de antigenios protectores contra as infeccoes e efeitos toxidos de bordetella
JPH02149529A (ja) 百日咳毒素のトキソイド化法
ATE258445T1 (de) Impfstoff beinhaltend bacterin und toxoid aus pasteurella haemolytica typ a-1
JPH06507420A (ja) 粘膜の病原体に対するワクチンとその製法
DK0623170T3 (da) Vacciner baseret på streptokinase
RU2185852C1 (ru) Способ вакцинопрофилактики дифтерии и столбняка на крайнем севере
Wells et al. Experimental Assessment of Parainfluenza Type 3 Virus Vaccines

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0937462

Country of ref document: EP

REN Ceased due to non-payment of the annual fee